Stock Alert: ADMA Biologics Rises 24%

(RTTNews) - Shares of ADMA Biologics Inc. (ADMA) are higher by more than 24 percent or $0.62 in Monday's morning trade at $3.14.

U.S. stocks are rising on Monday, extending gains from Friday's record highs, after the U.S. Food and Drug Administration or FDA approved emergency use of blood plasma to treat hospitalized COVID-19 patients.

ADMA Biologics manufactures specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. The company also joined the CoVIg-19 Plasma Alliance in May and has been collecting plasma from COVID-19 convalesced patients. The CoVIg-19 Plasma Alliance has been established to accelerate the development of a plasma-derived hyperimmune globulin therapy for COVID-19.

ADMA Biologics has traded in a range of $1.45 to $5.48 in the past 52 weeks.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More